The paper here is Italian (generally bad news - just think of Berlusconi!) and is really a pilot study. It is small, poorly controlled, unblinded, and has been done without ethics committee assent - it is after all, Italy! The results are encouraging, and support the general promotion that BLIS already uses. The authors say they are going to do a bigger study, which would certainly be needed.
As it is a “probiotic”, it is a nutriceutical and is not a registered medicine, so it can get away with relatively weak science data and generalisations about “supporting healthy” gums/ears/immunity and so on.
I think - but am not certain - that BLIS has not done as well as they might have liked with these bacterial probiotics. They have been going for quite a long time. I personally think that taking capsules full of bacteria is a hard sell, although techniques like BLIS Ice Cream is a good endeavor. However, should the major study come through positive - Probably 2 years away - BLIS might get a bit more cut through in the medical community.
I was with a friend of mine the other day who is very interested in these sort of companies and this is what he had to say about the paper:
"This paper is not the dawning of the new age but could be a good indicator for the future."
I have mixed feelings about the stock. The new distributor is a good sign, and there is definitely room to grow especially if they can break into Europe.
Guess we will see in March, or before then. Good luck to all those holding. You could make a ‘healthy’ return.
:)